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People affected by cancer want information about their prognosis but clinicians have trouble estimating and talking about it. We
sought to determine the nature and accuracy of medical oncologists’ estimates of life expectancy in newly referred patients with
incurable cancer. With reference to each patient, medical oncologists estimated how long they thought 90, 50, and 10% of similar
patients would live. These proportions were chosen to reflect worst case, predicted, and best case scenarios suitable for discussions.
After a median follow-up of 35 months, 86 of the 102 patients had died with an observed median survival of 12 months. Oncologists’
estimates of each patient’s worst case, predicted and best case scenarios were well-calibrated: 10% of patients lived for fewer months
than estimated for the worst 10% of similar patients; 50% lived for at least as long as estimated for 50% of similar patients (predicted
survival), and 17% lived for more months than estimated for the best 10% of similar patients. Oncologists’ estimates of each patient’s
predicted survival were imprecise: 29% were within 0.67–1.33 times the patient’s actual survival, 35% were too optimistic (41.33
times the actual survival), and 39% were too pessimistic (o0.67 times the actual survival). The proportions of patients with actual
survival times bounded by simple multiples of their predicted survival were as follows: 61% between half to double their predicted,
6% at least three to four times their predicted, and 4% no more than 1/6 of their predicted; similar to the proportions in an
exponential distribution (about 50%, 10% and 10% respectively). Ranges based on simple multiples of the predicted survival time
appropriately convey prognosis and its uncertainty in newly referred people with incurable cancer.
British Journal of Cancer (2006) 94, 208–212. doi:10.1038/sj.bjc.6602908 www.bjcancer.com
Published online 13 December 2005
& 2006 Cancer Research UK
Keywords: prognosis; communication; truth disclosure; physician-patient relations; survival analysis
                                                   
Most doctors in Western countries now tell patients their diagnosis
of cancer, but information about prognosis is less commonly
presented. We surveyed 187 people with breast cancer or
melanoma and found that only 27% reported a discussion of
prognosis around the time of their initial diagnosis (an average of
4 years earlier) (Schofield et al, 2001). In a subsequent audio-tape
audit of initial consultations with an oncologist in 118 patients
with incurable cancer, we found that about half were given some
information about life expectancy but only one-third were given a
quantified estimate (Gattellari et al, 2002). We developed and
tested a question prompt list designed to improve communication
when cancer patients see a medical or radiation oncologist for the
first time. In three separate randomised trials of this intervention,
prognosis was the only topic about which patients who received
the question prompt list asked more questions, even though only
two of the 17 suggested questions were about prognosis (Butow
et al, 1994; Brown et al, 1999, 2001). This failure to discuss
prognosis is probably caused as much by doctors’ uncertainty
about how to think and talk about prognosis as it is by patients’
reluctance to ask about it (Brown et al, 1999, 2001). Christakis and
Lamont (2000) reported that doctors were inaccurate in their
estimates of prognosis for terminally ill patients, and that their
errors were systematically optimistic. In their cohort of 468
patients whose median survival was 24 days, only 20% of survival
predictions met their criterion of accuracy (predicted survival
within 733% of actual survival); 63% were too optimistic and 17%
were too pessimistic. Lamont and Christakis (2003) have also
suggested that physicians may have difficulty finding the research
data they need to better estimate the survival of their patients with
advanced cancer.
The aim of this study was to determine the nature and accuracy
of medical oncologists’ predictions of survival in newly referred
people with incurable cancer.
PARTICIPANTS AND METHODS
Baseline characteristics (age, primary site, histology, date of
diagnosis, stage at diagnosis, current extent), prior treatment,
and planned treatment were recorded prospectively for all
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soutpatients referred to any one of the 11 medical oncologists at the
Royal Prince Alfred Hospital campus of the Sydney Cancer Centre,
NSW, Australia. Oncologists also recorded whether the intent
of future treatment was curative or noncurative. For patients in
whom the intent of treatment was noncurative, oncologists were
asked to complete three additional questions headed ‘Estimation of
prognosis’ as follows:
‘If a group of patients had a similar stage of cancer and
prognostic factorsy
What is the length of time (months) 90% would survive?—;
What is the length of time (months) 50% would survive (i.e.
median survival)? —;
What is the length of time (months) the best 10% would
survive?—.
There was no further specification of what ‘similar stage of
cancer and prognostic factors’ meant. Participating oncologists
understood that the ‘length of time 50% would survive (i.e. median
survival)’ was asking for the oncologist’s best estimate of how long
that individual patient would live. This estimate of life expectancy
is referred to as the ‘predicted survival’ in this paper. These
questions were designed to elicit predictions that might be used in
discussions with patients to reflect worst case, typical, and best-
case scenarios.
All data were recorded on a single page form that is completed
as part of routine clinical practice for all patients referred to our
unit, generally within a week or two of their first consultation, after
any additional tests had been completed. The study was considered
an audit of standard practice. It involved no additional questions,
tests, or interventions for patients, had no effect on their medical
care, and did not involve any external research personnel. Ethics
clearance and patient consent are not required for such audits in
Australia.
The sampling frame for this study consisted of 500 consecutive
newly referred outpatients seen over a 5-month period. Estimates
of prognosis were available for 102 of the 205 patients in whom the
intent of treatment was considered noncurative (response-rate of
50%). We did not try to determine why estimates of prognosis
were not recorded for the other 50% of patients with incurable
cancer. Just over half were referred by surgeons, approximately
15% by local doctors, 11% by physicians, and the remainder by
gynaecologists or radiation oncologists.
The objectives of the analysis were descriptive and exploratory.
Durations of survival and follow-up are described with the
Kaplan–Meier product-limit method and are based on all 102
patients. Comparisons of predicted survival with observed survival
include all 102 patients. The findings and conclusions were
unaffected by excluding patients who were alive at the last
follow-up.
RESULTS
The patients’ baseline characteristics are summarized in Table 1
and are typical of people with advanced cancer newly referred to
our centre. Most were symptomatic, older than 50 years, and had
some form of anticancer treatment recommended.
After a median follow-up of 35 months, 86 of the 102 died. Their
survival distribution is shown in Figure 1. The median survival of
the cohort was 12 months (range 2 weeks–38 months). The figure
illustrates that the observed survival distribution was closely
approximated by an exponential distribution with a median
survival of 12 months.
Oncologists’ predictions were well-calibrated. Half the patients
(50%) lived at least as long as their oncologist’s ‘predicted survival’
(the number of months 50% of similar patients would survive);
10% lived fewer months than their oncologist predicted for the
worst 10% of similar patients; 17% lived more months than their
Table 1 Baseline characteristics (n¼102)
Age in years
Median 64
Interquartile range 55–73
Range 16–96
Female (%) 41
Tumour type (%)
Lung 18
Colorectal 11
Breast 10
Carcinoma of unkown primary site 9
Melanoma 8
Prostate 7
Liver 5
Kidney 4
Ovary 4
Bladder 3
Stomach 3
Other 26
Previous anticancer treatment (%)
Surgery 59
Hormone therapy 13
Radiation therapy 13
Chemotherapy 7
None 34
Symptomatic (%) 73
Type of treatment planned (%)
Chemo 57
Radiation 22
Hormonal 45
Observation 10
Surgery 1
Other 4
Nature of treatment planned (%)
Standard 62
Clinical Trial 15
Other 14
None 9
Observed and exponential survival
102 73 52 35 26 17 7
Numbers at risk
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Figure 1 Observed survival distribution (step function) and an
exponential distribution based on a median survival of 12 months (smooth
curve).
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soncologist predicted for the best 10% of similar patients. There was
a strong correlation between the oncologists’ predicted survival
and their patients’ actual survival (Spearman’s rank correlation
r¼0.60, Po10
 6).
Oncologists’ predictions were imprecise. Figure 2 illustrates the
relationship between the oncologists’ predicted survival for each
patient and their actual survival. Most predicted survivals were
simple multiples of 3 or 4 months (e.g. 3, 4, 6, 8, 9, 12, 18 and 24
months). Figure 3 shows the actual survivals for subgroups of
patients with similar predicted survivals. The range of actual
survivals within each subgroup is wide and skewed towards longer
times. The actual median survival for each subgroup is close to
that predicted.
Few patients had actual survival times close to their oncologist’s
predicted survival. In all, one-twentieth (5%) lived within a month
of their oncologist’s predicted survival, one-sixth (18%) lived
within 2 months of it, and one-third (32%) lived within 3 months
of it. Only 29% of oncologists’ predicted survivals met Christakis’
criterion of accuracy by falling within 33% of the patient’s actual
survival (i.e. predicted survival between 0.67 and 1.33 times the
actual survival). Similar proportions of the predictions were either
too optimistic (35% of predictions more than 1.33 times the actual
survival) or too pessimistic (39% of predictions o0.67 times the
actual survival).
The proportions of patients with actual survival times bounded
by simple multiples of their predicted survival time were similar to
those expected in an exponential distribution. About one-third of
patients (35%) lived between 0.67 and 1.5 times their predicted
survival time, and about half (61%) lived between half to double
their predicted survival time, 6% lived for at least three to four
times their predicted survival time, and 4% lived for no more than
1/6 of their predicted survival time. These proportions are similar
to those bounded by the multiples of the median survival in an
exponential distribution: 28% of values between 0.67 to 1.5 times
the median, and 46% between half to double the median, 10%
more than three to four times the median, and 10% o1/6 of the
median.
DISCUSSION
Oncologists’ predictions were well-calibrated but imprecise. Few
patients had actual survival times close to their oncologist’s
prediction, but there was no systematic tendency for oncologists to
either overestimate or underestimate, and substantial proportions
of patients lived within simple multiples of their oncologist’s
predictions. The strengths, limitations and implications of these
observations are discussed below.
The strength of this study is its prospective design and follow-
up. Survival predictions were made at or near the initial
consultation. Only 16 people were still alive at the time of our
analysis. This biases our estimates of actual survival downwards,
but has little effect on estimates of median survival (either for all
patients, or for subgroups). Including or excluding these people
from the analyses had little effect on the findings. However, an
analysis performed after these 16 people die would be likely to
show that oncologists underestimated the survival times of those
who lived longest.
The main limitations of this study are its size and response rate.
There are too few patients and oncologists to draw conclusions
about subgroups. The accuracy of our predictions is probably
overestimated because the prognosis in patients for whom
predictions were recorded was probably more straightforward
than that in patients for whom predictions were not recorded.
However, the group’s median survival of 12 months is almost
identical to that of complete cohorts of our patients with incurable
cancer from 1977 to 1993 (Milsted et al, 1980; Chye et al, 1984).
Our results are probably best considered to reflect a group of
newly referred patients with incurable cancer for whom onco-
logists were willing to record estimates of prognosis.
Most previous studies of prognostication in incurable cancer
have been in people with far-advanced disease being referred for
end-of-life care, not in people recently diagnosed and being
referred to medical oncologists for consideration of anticancer
treatment. These studies have shown that doctors’ predictions were
inaccurate, with a tendency to overestimate life expectancy
(Vigano et al, 1999, 2000a,b; Christakis and Lamont, 2000).
People in these previous studies were being admitted to hospices
or hospice programmes and most died within a few weeks or
months. Christakis and Lamont (2000) defined predictions that
were within 733% of the observed survival as accurate,
predictions o0.67 times the observed survival as too pessimistic,
and predictions 41.33 times the observed survival as too
optimistic. In their study of 468 terminally ill people referred to
an outpatient hospice programme with a median survival of 24
days, 20% of predictions made by referring clinicians’ were
accurate, 63% were too optimistic, and 17% were too pessimistic.
In our study, a higher proportion of predictions were accurate
(29%), while similar proportions were either too optimistic (35%)
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Figure 2 Observed versus predicted survival for each individual. Points
on the 45 degree line signify people who lived exactly as long as predicted,
points above the line signify people who lived longer than predicted, points
below the line signify people who lived shorter than predicted. There is a
strong association between predicted and observed survival (Spearman’s
rank correlation of 0.60, Po10
 6).
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Figure 3 Observed survival for subgroups with similar predicted
survivals. The categories (range of included predictions, and number of
patients) are: 3 months (2–4, n¼10); 6 months (5–7, n¼17); 9 months
(8–10, n¼31); 12 months (11–14, n¼16); 18 months (15–20, n¼10);
24 months (21–29, n¼9); 36 months (429, n¼9). The boxes extend
from the upper quartile (75th percentile) to the lower quartile (25th
percentile) and include the middle 50% of patients. The solid circle
represents the median (50th percentile). The whiskers extend to the
maximum and minimum value.
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sor too pessimistic (39%). MacKillop and Quirt’s (1997) findings in
their study of 39 patients with advanced cancer and a median
survival of 14 months are similar to ours: 31% of oncologists’
predictions were accurate, 38% were too optimistic and 31% were
too pessimistic. The lower accuracy and tendency to overestimate
life expectancy in Christakis and Lamont’s study probably reflects
their population’s shorter survival, and the large number of
generalist physicians less familiar with advanced cancer.
The distribution of our group’s actual survival times was skewed
to the right (towards longer times), as are most survival
distributions. This is because the minimum survival time can be
no shorter than 0, whereas the maximum survival time can be
many years. The same constraints should apply to estimates for an
individual. Someone with a predicted survival of 6 months can die
no sooner than immediately, but may live for several years. This
suggests that if ranges are to be estimated around a predicted
survival, then they should also be asymmetrical – the interval
above the predicted survival should be larger than the interval
below it.
The good fit of an exponential model was fortuitous (the first
and only fit we tried) and surprising because our population
included a mixture of types and extents of advanced cancer with
different expected survival durations. We are not suggesting
that the survival distributions of all groups of cancer patients are
exactly exponential. More homogeneous groups should have
survival curves that are sigmoidal (steeper in the middle, flatter
at the beginning and end); more heterogeneous groups should
have survival curves better approximated by a declining expo-
nential (steeper at the beginning and flatter at the end). However,
keeping the exponential shape in mind is helpful in thinking and
talking about predictions of life expectancy, even if it does not
provide an exact fit.
The median survival is the time taken for a group to be halved
(half still alive, half already dead), and in an exponential
distribution, this time is constant along the whole curve and
analogous to the half-life of radioactive decay. So, in an
exponential distribution the proportion remaining after two half-
lives is 25%, after three half-lives is 12.5%, and after four half-lives
is 6.25%.
These observations have important implications for how we
might think and talk about predicted life expectancy. Firstly, the
predictions were well-calibrated, so predicting the median survival
of a group of similar patients seems a reasonable starting point.
Secondly, predictions were imprecise and probabilistic, so it is
probably better to think and talk about ranges (e.g. 6–18 months)
than about single point estimates (e.g. 9 months). Thirdly, survival
times are skewed to the right (towards longer times), so ranges
around any point estimate (for example the predicted median
survival) should be asymmetrical with wider intervals above than
below. Fourthly, it is helpful to think of median survivals as half-
lives and to use simple multiples of the predicted median survival
(e.g. half to double) to construct ranges. This corresponds with
Lamont and Christakis’ recommendation to discuss the inter-
quartile range – half the median estimates the upper quartile (75%
live at least this long), and double the median estimates the lower
quartile (25% live at least this long) (Lamont and Christakis, 2003).
Lastly, rough predictions of the best and worst case scenarios
might be estimated as about three to four times, and 1/6 of the
predicted median, respectively.
The stereotypical question about life expectancy – ‘How long
have I got?’ – begs a simple, single-number answer. Unfortunately,
the stereotypical, simple, single-number answer – ‘6 months’ for
example – is as misleading as it is unsympathetic. A single number
suggests greater precision than is warranted, and is often
interpreted as a limit – ‘the last doctor said I had only 6 months,
but that was a year ago and I’m still going strong’. We suggest it
may be better to think and talk about ranges based on an
exponential model. Box 1 outlines the suggested steps for
predicting life expectancy in people with advanced cancer using
this approach. We recommend deliberately leaving estimates
rough to accurately convey their inherent imprecision.
Before discussing estimates of life expectancy with an individual,
it is important to determine what kind of information they want.
Do they want any information at all, and if so, would they prefer
orders of magnitude (e.g. days to weeks, weeks to months, months
to years); lengths of time (e.g. numbers of days, weeks, months or
years); or probabilities (e.g. the chance of living a given length of
time)? Box 2 gives examples of how estimates of life expectancy
might be discussed and explained, depending on the patient’s
information preferences.
Our data do not indicate how to improve the accuracy of
individual predictions. We asked oncologists to estimate ‘how
many months 50% of similar patients would survive’; asking them
‘how many months do you think this patient will survive’ might
have resulted in different answers. There was a strong correlation
between oncologists’ predictions and their patients’ actual survival
times. However, over half the variation in patients’ survival times
remained unexplained. The prognostic importance of performance
status and quality of life are well documented in advanced cancer
(Stockler et al, 1999; Chow et al, 2002). Symptoms and signs of
advanced cancer, nutritional status, and laboratory tests have also
been identified as important (Maltoni and Amadori, 2002). At the
time of initial referral to a medical oncologist, other factors may
also be important, such as disease tempo, response to previous
treatments, co-morbidities, and planned future treatments. Better
understanding of these factors and their significance should help
doctors refine and improve the accuracy of their predictions.
However, it may be that life expectancy, like many other complex
phenomena, is inherently unpredictable and the best we can do is
improve our appreciation and communication of this uncertainty.
Estimates of life expectancy are essential for rational decision-
making, planning and management in people with advanced
cancer, many of whom want more information about their
prognosis. Describing life expectancy with approximate ranges
based on simple multiples of the predicted median survival of a
group of similar patients appropriately conveyed prognosis and its
uncertainty in newly referred patients with advanced cancer. An
appreciation of life’s inherent unpredictability and how to describe
it should help clinicians better meet the needs of those affected by
advanced cancer.
Box 1
Steps for predicting life expectancy
1. Estimate the median survival of a group with similar characteristics
2. Adjust the median survival from the group to account for differences
with the individual
3. Estimate the range for the middle half of patients by taking half to
double the predicted median
4. Estimate the best and worst case scenarios as B1/6 of, and three to
four times, the predicted median
5. Adjust the best and worst case scenario estimates to account for any
outstanding differences or biases
Box 2
Examples of phrases for talking about life expectancy
1. The typical person with your type and stage of cancer lives X months.
This means that half the people live more than X months and half the
people live less than X months
2. About half the people with your type and stage of cancer live between
X/2 and 2X months
3. If we had 100 people exactly like you, then we did expect that the 10
who did best to still be around in 3–4X months, whereas the 10 who did
worst would be in trouble within X/6 months
4. It might be as short as a few months or as long as a few years
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